Press Release

March 05, 2021
1 min read

Azura MGD treatment meets primary endpoints in phase 2 trial


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Significant improvement in signs and symptoms of meibomian gland dysfunction were achieved with AZR-MD-001, a topical ointment, thus meeting the primary endpoints of the drug’s phase 2 trial, Azura Ophthalmics announced in a press release.

In the multicenter, double-masked, vehicle-controlled, integrated analysis of four separate phase 2 studies, safety and efficacy of AZR-MD-001 were analyzed for doses of 0.1%, 0.5% and 1% in 95 patients.

Statistically significant reduction of symptoms as measured by Ocular Surface Disease Index scores was demonstrated in the 0.5% and 1% groups (both P < .01) and in the 0.5% group (P < .05) at 3 months, according to the release. Additionally, after 3 months of treatment, a statistically significant proportion of patients, up to 58% (P < .05), were non-symptomatic compared with 16% of patients in the control group.

Up to 46% of patients achieved a clinically meaningful increase in the number of glands secreting meibum compared with 8% in the control group, the release said.

No serious ocular treatment emergent adverse events were reported. Application site irritation, stinging on application and watery eyes were reported only in the 1% dose group.